Research programme: protein serine threonine kinase inhibitors - BioBlocks/Visionary Pharmaceuticals

Drug Profile

Research programme: protein serine threonine kinase inhibitors - BioBlocks/Visionary Pharmaceuticals

Alternative Names: Serum and glucocorticoid-regulated kinase 1 inhibitors - BioBlocks/Visionary Pharmaceuticals; SGK1 inhibitors - BioBlocks/Visionary Pharmaceuticals

Latest Information Update: 18 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioBlocks; Visionary Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Breast cancer; Solid tumours

Most Recent Events

  • 16 Apr 2016 Serum- and glucocorticoid-regulated kinase 1 inhibitors are still in early research phase for Breast cancer and Solid tumors in USA
  • 08 Jan 2014 Early research in Breast cancer in USA (unspecified route)
  • 08 Jan 2014 Early research in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top